Evidence map›Paper›PMID 21173013›Full record

Trial reportAnnals of the rheumatic diseases2011

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).

Pierre Quartier, Florence Allantaz, Rolando Cimaz, Pascal Pillet, Claude Messiaen, Christophe Bardin, Xavier Bossuyt, Anne Boutten, Jacques Bienvenu, Agnes Duquesne and 7 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Annals of the rheumatic diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00339157 (ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset), which is not on this map. Cited by 256 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
256citing papers in PubMed, 16 pooled it
20.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00339157 phase2 / phase3completednot on this map

ANAkinra in Severe Juvenile Idiopathic Arthritis of Systemic Onset (ANAJIS)

TypeinterventionalSponsorInstitut National de la Santé Et de la Recherche Médicale, FranceRan2006 to 2008Enrolled24ConditionsSystemic-Onset Juvenile Idiopathic ArthritisArmsAnakinra, Pneumo23, Placebo
3 · Its place in the literature

Who cites it

256 citing papers in PubMed, 16 syntheses or guidelines pooled it, 547 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Guideline
  8. Pooled it
  9. Guideline
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Trial
  20. Trial

196 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Pierre QuartierUniversité Paris-Descartes and Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Paris, France. pierre.quartier@nck.aphp.fr
Florence Allantaz
Rolando Cimaz
Pascal Pillet
Claude Messiaen
Christophe Bardin
Xavier Bossuyt
Anne Boutten
Jacques Bienvenu
Agnes Duquesne
Olivier Richer
Damien Chaussabel
Agnes Mogenet
Jacques Banchereau
Jean-Marc Treluyer
Paul Landais
Virginia Pascual
Assistance Publique – Hôpitaux de Paris · FRHôpital Femme Mère Enfant · FRHôpital Necker-Enfants Malades · FRHôpital Pellegrin · FRUniversité Paris Cité · FRHôtel-Dieu de Paris · FRIcahn School of Medicine at Mount Sinai · USKU Leuven · BEUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA).

methodsA multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective was to compare the efficacy of a 1-month treatment with anakinra (2 mg/kg subcutaneous daily, maximum 100 mg) with a placebo between two groups each with 12 patients with SJIA. Response was defined by a 30% improvement of the paediatric American College of Rheumatology criteria for JIA, resolution of systemic symptoms and a decrease of at least 50% of both C-reactive protein and erythrocyte sedimentation rate compared with baseline. After month 1 (M1), patients taking placebo were switched to anakinra. Secondary objectives included tolerance and efficacy assessment for 12 months, and analyses of treatment effect on blood gene expression profiling.

resultsAt M1, 8/12 responders were receiving anakinra and 1 responder receiving placebo (p=0.003). Ten patients from the placebo group switched to anakinra; nine were responders at M2. Between M1 and M12, six patients stopped treatment owing to an adverse event (n=2), lack of efficacy (n=2) or a disease flare (n=2). Blood gene expression profiling at enrollment and at 6 months' follow-up showed one set of dysregulated genes that reverted to normal values in the clinical responders and a different set, including interferon (IFN)-inducible genes, that was induced by anakinra.

conclusionsAnakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. TRIAL REGISTRATION NUMBER: NCT00339157.

Indexed as

AdolescentAntibodies, BacterialAntirheumatic AgentsArthritis, JuvenileBiomarkersBlood SedimentationChildChild, PreschoolC-Reactive ProteinDouble-Blind MethodFemaleGene Expression ProfilingHumansInterleukin 1 Receptor Antagonist ProteinMalePneumococcal Vaccines23-valent pneumococcal capsular polysaccharide vaccineAntibodies, BacterialAntirheumatic AgentsBiomarkersC-Reactive ProteinInterleukin 1 Receptor Antagonist ProteinPneumococcal VaccinesPolysaccharides, Bacterial

Identifiers

PMID21173013
PMCPMC3070271
OpenAlexW2166106092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.